

**10. Title: Medicaid Extended Postpartum Coverage and Continuous Eligibility for Children**

Type of Request: Extension of a currently approved collection.

CMS ID Number: CMS-10434 #77.

OMB Control Number: 0938-1188.

eRulemaking Docket ID Number: CMS-2023-0088.

Docket Web Address: <https://www.regulations.gov/docket/CMS-2023-0088>.

For Policy Related Questions, Contact: Alexa Turner at 410-786-8823.

**William N. Parham, III,**

Director, Division of Information Collections and Regulatory Impacts, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2024-08658 Filed 4-22-24; 8:45 am]

BILLING CODE 4120-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Proposed Information Collection Activity; Community Services Block Grant (CSBG) Model Tribal Plan and Application (New Collection)**

**AGENCY:** Office of Community Services, Administration for Children and Families, U.S. Department of Health and Human Services.

**ACTION:** Request for public comments.

**SUMMARY:** The Office of Community Services (OCS), Administration for Children and Families (ACF), requests an approval of the Community Services Block Grant (CSBG) Model Tribal Plan.

**DATES:** Comments due within 60 days of publication. In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

**ADDRESSES:** You can obtain copies of the proposed collection of information and submit comments by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). Identify all requests by the title of the information collection.

**SUPPLEMENTARY INFORMATION:**

*Description:* Section 677 of the CSBG Act requires Indian tribes or tribal organizations to submit an application and plan (CSBG Model Tribal Plan). The CSBG Model Tribal Plan must meet statutory requirements prior to OCS awarding CSBG tribal grant recipients with CSBG funds. Tribal grant recipients have the option to submit a detailed plan annually or biannually. Tribal grant recipients that submit a biannual plan must provide an abbreviated plan the following year if substantial changes to the initial plan will occur. The CSBG Model Tribal Plan has been used in previous years without OMB approval. To come into compliance with the PRA, ACF is submitting the CSBG Model Tribal Plan as a new request to OMB.

*Respondents:* Tribal grant recipients (tribes and tribal organizations)

**ANNUAL BURDEN ESTIMATES**

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
CSBG Model Tribal Plan .....	66	1	10	660

*Comments:* The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

*Authority:* Sec. 677, Pub. L. 105-285, 112 Stat. 2742 (42 U.S.C. 9911)

**Mary C. Jones,**

ACF/OPRE Certifying Officer.

[FR Doc. 2024-08668 Filed 4-22-24; 8:45 am]

BILLING CODE 4184-27-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2024-N-1786]

**PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**DATES:** Approval is withdrawn as of May 23, 2024.

**FOR FURTHER INFORMATION CONTACT:**

Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137, [Kimberly.Lehrfeld@fda.hhs.gov](mailto:Kimberly.Lehrfeld@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.